ARCADIA Coordinator Webinar

Slides:



Advertisements
Similar presentations
CMRSC Division of Hematology/Oncology
Advertisements

Tips to a Successful Monitoring Visit
ProTECT III Regulatory & Project Management. Project Spoke Table This is where information about your Spokes is maintained This is where information about.
Neurological Emergencies Treatment Trials Network RAMPART This award is funded with support of NINDS, BARDA and the NIH CounterACT program.
Identification & Distinction of Clinical Trial Participant Charges Bethany Martell Office of Clinical Research Associate Director- Financial Operations.
Determining % Effort for Clinical Trial Kathy Price, RN, MBA Manager, GI Clinical Research.
Clinical Trial Infrastructure in Centres Lillian L. Siu Princess Margaret Hospital.
Research and Development Protocol Submission and Continuing Review Processes Kimberly Summers, PharmD Assistant Chief for Clinical Research South Texas.
Common Audit Findings UTHSC Institutional Review Board (IRB)
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.
Arthi Ramakrishnan SHINE Site Manager Stroke Hyperglycemia Insulin Network Effort (SHINE) Stroke Hyperglycemia Insulin Network Effort (SHINE) Regulatory.
Investigational Devices and Humanitarian Use Devices June 2007.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Responsibilities of Sponsor, Investigator and Monitor
MTN-025/HOPE Decliner Population Procedures. Who are the Decliner Population? Former ASPIRE participants who decline or express no interest in joining.
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Remote Site Initiation Visits
Clinical Trial Budgets
We will begin the MaRISS Coordinator Call shortly…
PRCSG Training Webinar: Budget for Industry Sponsored Studies
IMPAACT 2010 Screening Visits
The Role and Responsibilities of the Clinical Research Coordinator
IMPAACT 2010 Screening Visits
Responsibilities of Sponsor, Investigator and Monitor
MAINTAINING THE INVESTIGATOR’S SITE FILE
Investigator of Record – Definition
Field Inventory Services-Sanofi Inventory and Audit Training
Captains and Fixtures Secretaries Training 2016/17
ARCADIA Study Coordinator Training
IMPAACT 2010 Screening Visits
We will begin the MaRISS Coordinator Call shortly…
How-to CTA & Start-up Documents Webinar October 25th, 2018
ClinicalTrials.gov PRS – How to Register and Maintain a Record
Elements of an Organized Regulatory Binder
Claire McKinley, PMP, CCRP
HOW TO ENTER BASELINE DATA
PI and Coordinator Webinar
The HIPAA Privacy Rule and Research
HOW TO SCREEN PATIENTS AND BOOK THE BASELINE VISIT APPOINTMENT?
PI and Coordinator Webinar
Investigator of Record – Definition
Investigator of Record – Definition
EPIC Tools for Clinical Research
Michael Linke, PhD, CIP Professor Department of Internal Medicine
PI and Coordinator Webinar
National Hospital for Neurology and Neurosurgery,
MAINTAINING THE INVESTIGATOR’S STUDY FILE
PI and Coordinator Webinar
E-CRF Overview Oracle® Clinical Remote Data Capture Training (Version 4.6 HTML) e-CRF Completion John McDonach Manager CDM, PPD.
Clinical Trial Budgets
Clinical Trial Budgets
TRTO (Translational Research Trials Office)
PI and Coordinator Webinar
PI and Coordinator Webinar
Epic Tools for Clinical Research
EPIC Tools for Clinical Research
“How to” CIRB, Regulatory, and WebDCU™ Overview July 25, 2019
Sleep SMART Clinical Trial Agreements / Regulatory Webinar
Michael Linke, PhD, CIP Professor Department of Internal Medicine
How-to CTA & Start-up Documents Webinar October 25th, 2018
Epic Tools for Clinical Research
PI and Coordinator Webinar
Central IRB Components of ARCADIA
MOST Study Update and Protocol Refresher
PI and Coordinator Webinar
Presentation transcript:

ARCADIA Coordinator Webinar Irene Ewing, RN BSN ARCADIA Project Manager Feb 28, 2018

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA) First Site released to enroll 2/1/2018 Three Subjects have been enrolled to date None randomized- have not met atrial cardiopathy criteria

Trial Status Update Currently have 117 Sites Signed Protocol Trial Agreement-62 sites with fully executed PTA CIRB submission/Approval- 47 submitted/26 approved Readiness calls- 12 completed

ARCADIA Webinar overview Project Document Requirements Pharmacy Site Readiness Screening /Eligibility Enrollment/Randomization Follow-up *CIRB- Sue Roll, RN BSN

Project document requirements Delegation of Authority Log List all team members One 1 PI and 1 primary Coordinator must be identified Pharmacist Identify responsibilities- all must be assigned StrokeNet COI required for all investigators and coordinators If you edit this after your CIRB this constitutes an administrative amendment

Site Documents FWA- https://ohrp.cit.nih.gov/search/search. Protocol Signature Page- version 3 CIRB approval-upload after CIRB approval Informed Consents-upload after CIRB approval Administrative Amendments-upload if/when there are changes Recruitment Material-NA at this time

People Documents CV- signed/dated, expires every 5 years Medical Licenses –can waive if not applicable mRS- expires every 2 years unless indicated otherwise NIHSS-expires every 2 years unless certificate indicates otherwise Specimen Shipping certificate- expires every 2 years StrokeNet COI- expires annually Protocol and Study Coordinator training

https://webdcu.musc.edu/campus/ Protocol training & attestation form Study coordinator training & attestation form Pharmacy training video Data training video NIHSS and mRS training links

Contacts

Pharmacy set up Trial designed that each site would use their institutional pharmacy or Investigational pharmacy. Study Drug is being shipped from BMS and packaged at the central pharmacy here at the NCC. The central pharmacy must follow the Ohio Board of Pharmacy laws as well as the state laws where they are shipping study drug. WebDCU document requirements: Pharmacy License uploaded under site documents Pharmacist should be listed on your DOA and their license uploaded to webdcu under the people documents

Pharmacy Exceptions Some ARCADIA sites do not have access to a hospital or IDS pharmacy Important to note that the central pharmacy is not automatically able to ship study drug to a clinic or office even if you have done this for other studies. **These situations will be evaluated on a individual basis. Before the central pharmacy can ship study drug to a non-pharmacy: 1. You need to determine what the Board of Pharmacy in your state allows. 2. Is the Site PI/MD permitted by the Medical Board in your state to dispense study medication. * In this situation the MD medical license will take the place of the pharmacy license requirement.

Site Readiness Study Drug will be shipped and Readiness Calls will be scheduled : PTA signed CIRB approval Pharmacy license in place State pharmacy license confirmed Shipping address is confirmed The site PI, Site primary coordinator need to be on this call. Other members of the site team are invited and encouraged. The checklist is sent in advance so sites can review and discuss with their team members.

Site Readiness Following the Readiness call your site will be “released to enroll” Confirm study drug and lab supplies are at your site All local IRB / institutional approvals have been received All required regulatory documentation is uploaded All user permissions have been set up and approved

Screening

Screening Procedures to Identify Atrial Cardiopathy Standard-of-care ECG tracing scanned, de-identified and uploaded to WebDCU- it will be evaluated by the core lab for PTFV1 measurement Blood sample shipped to core lab for NT-proBNP assay Standard-of-care echocardiogram for left atrial size measurement, interpreted locally, enter Atrial Diameter in webdcu. If a patient is eligible based on this criteria, you will be notified by webDCU™ and can proceed with randomization. Otherwise you will wait on the NT-ProBNP and ECG results which will be available in webDCU™ within 24-48 hours.

The Echo and the 12-lead ECG must have been done after the index stroke. These are standard of care and should not be done for the purpose of the study. It is permissable to use the Echo and ECG done at an outside facility if you can obtain a copy. Always de-identify before uploading or sending the DVD

Eligibility Questions The ARCADIA hotline 1-833-427-2234 is available to help with reviewing screening data and determining eligibility as well as for emergency unblinding.

Screening Patients can be enrolled 3-120 days after stroke Screening and randomization can both occur during initial hospitalization in certain cases, but in most situations these visits will be on separate days. Once the patient is consented they are enrolled and will receive a study ID. Baseline Visit information should be entered into WebDCU™

Randomization Once you are notified that an enrolled subject meets one of the eligibility criteria you should schedule the randomization visit. This should be done as soon as possible after the BL visit. It can be the same day if the subject qualifies based on the echo. If done at a later time, you should verify the patient still qualifies based on I/E criteria. You do not need to repeat any of the exams except a new set of vitals signs should be collected. The study drug should be started within 24 hours of randomization. *If the subject does not qualify you need to enter end of study visit CRFs.

Subject Follow-up Schedule of Events listed in the Protocol and the MOP Follow-up visit 1 (30 +/- 7 days) phone call Follow-up vists are every 3 months for the first year. After 12 months in person visits are every 6 months, but medication refills are still every 3 months. Discuss with your team what your plan is for study medication refills after 12 months. The protocol allows mailing of study drug and home visits if permitted in your state and institution. Bringing the patient back in every 3 months is ideal.

Data Entry CRFS should be entered within 5 days of the visit If an SAE or outcome event is reported to you please enter this information within 24 hours of becoming aware of it We realize you may have very limited information up front but report what you can. There are event packets posted to guide you on what documents you will need to collect.

Questions? FAQ list is posted in WebDCU toolbox/project documents. There is also a link on the ARCADIA Page for FAQ help.